Albany Molecular Research (AMRI) Posts Q4 adj.-EPS of 17c; Issues Strong FY13 Outlook
Tweet Send to a Friend
Albany Molecular Research (NASDAQ: AMRI) reported Q4 EPS of $0.17, $0.08 better than the analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE